银屑病血管炎症试验中阿达木单抗、光疗与安慰剂的患者报告结局
本研究为多中心随机安慰剂对照试验的二次分析,纳入97例银屑病患者,评估阿达木单抗和窄谱中波紫外线光疗对健康相关生活质量的影响。第12周时,阿达木单抗和光疗组达到DLQI最小临床重要差异的几率均高于安慰剂组;光疗组在EQ-5D-3L指数达到最小临床重要差异的几率高于安慰剂组和阿达木单抗组。
要点
- 光疗和阿达木单抗均能改善银屑病患者皮肤相关及整体健康相关生活质量。
- 第12周时,光疗在整体健康相关生活质量改善上优于阿达木单抗。
- 光疗对比安慰剂在EQ-5D-3L指数达到MCID的OR为9.78(95%CI 2.99-31.95)。
核心结论
- 光疗和阿达木单抗均能改善银屑病患者的皮肤相关生活质量和整体健康相关生活质量。
- 光疗在整体健康相关生活质量改善方面优于阿达木单抗。
研究设计与样本
- 多中心、随机、安慰剂对照试验(ClinicalTrials.gov no. NCT01553058)的患者报告结局分析。
- 共纳入97例银屑病患者,每4周评估DLQI和EQ-5D-3L。
主要发现
- 第12周时,阿达木单抗组达到DLQI最小临床重要差异的OR为2.88(95%CI 1.02-8.17),光疗组OR为8.83(95%CI 2.47-31.57),均高于安慰剂组。
- 光疗对比安慰剂在EQ-5D-3L指数达到最小临床重要差异的OR为9.78(95%CI 2.99-31.95)。
- 光疗对比阿达木单抗在EQ-5D-3L指数达到最小临床重要差异的OR为4.07(95%CI 1.42-11.70)。
临床怎么用
- 对于银屑病患者,光疗和阿达木单抗均可作为改善生活质量的治疗选择。
- 若更关注整体健康相关生活质量的改善,光疗可能更具优势。
局限性
- 样本量小。
- 为二次分析。
- 结果普适性受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data about the impact of narrowband ultraviolet B phototherapy on patient-reported measures of health-related quality of life. OBJECTIVE: To evaluate the impact of adalimumab and phototherapy on health-related quality of life. METHODS: We examined patient-reported outcomes from a multicenter, randomized, placebo-controlled trial (ClinicalTrials.gov no. NCT01553058). The Dermatology Life Quality Index and EQ-5D-3L were evaluated every 4 weeks. RESULTS: We enrolled 97 patients: 30.9% were female, mean age was 43.5 years (standard deviation, 14.0), and median Psoriasis Area and Severity Index score was 16.7 (interquartile range, 13.9-21.6). At week 12, patients being treated with adalimumab (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.02-8.17) and phototherapy (OR, 8.83; 95% CI, 2.47-31.57) were more likely to achieve the minimal clinically important difference in the Dermatology Life Quality Index compared with those receiving placebo. There were higher odds of achieving the minimal clinically important difference for the EQ-5D-3L Index score when comparing phototherapy versus placebo (OR, 9.78; 95% CI, 2.99-31.95) and phototherapy versus adalimumab (OR, 4.07; 95% CI, 1.42-11.70). LIMITATIONS: Small sample size, secondary analysis, generalizability. CONCLUSION: Phototherapy and adalimumab both improve skin-related quality of life and overall health-related quality of life compared with placebo in patients with psoriasis; however, patients treated with phototherapy achieved more improvement in overall health-related quality of life compared with patients treated with adalimumab.
引用
- Noe MH, Wan MT, Shin DB, et al. Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. J Am Acad Dermatol. 2019. PMID: 31163241. doi:10.1016/j.jaad.2019.05.080
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。